

Martin Å imkoviÄ•

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7339395/publications.pdf>

Version: 2024-02-01

61
papers

1,580
citations

516710

16
h-index

330143

37
g-index

64
all docs

64
docs citations

64
times ranked

1796
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. <i>Haematologica</i> , 2022, 107, 2108-2120.	3.5	53
2	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. <i>Journal of Clinical Oncology</i> , 2022, 40, 7538-7538.		66
3	Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia. <i>Onkologie (Czech Republic)</i> , 2022, 16, 151-154.	0.1	0
4	Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7538-7538.	1.6	1
5	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	5.2	22
6	Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1031-1043.	10.7	76
7	Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13421.	3.4	1
8	Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks. <i>Scientific Reports</i> , 2021, 11, 322.	3.3	6
9	Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Qéelite by the Czech CLL Study Group. <i>British Journal of Haematology</i> , 2021, 193, 769-778.	2.5	9
10	Recommendations for chronic lymphocytic leukaemia diagnosis and therapy 2021. <i>Transfuzie A Hematologie Dnes</i> , 2021, 27, 91-106.	1.0	2
11	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. <i>Annals of Hematology</i> , 2021, 100, 1733-1742.	1.8	10
12	Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. <i>Cancers</i> , 2021, 13, 3134.	3.7	6
13	External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. <i>British Journal of Haematology</i> , 2021, 193, 133-137.	2.5	4
14	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2021, 106, 2354-2363.	3.5	62
15	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
16	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	1.4	22
17	Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 393-393.	1.4	10
18	Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2® with the Clllear and Lyon-Sud Rw Databases. <i>Blood</i> , 2021, 138, 4679-4679.	1.4	0

#	ARTICLE	IF	CITATIONS
19	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. <i>Blood</i> , 2021, 138, 70-70.	1.4	20
20	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1
21	CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S220-S221.	0.4	1
22	Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The <sc>GOĀĈLEAR</sc> Study by the Czech <sc>CLL</sc> Study Group. <i>Hematological Oncology</i> , 2020, 38, 509-516.	1.7	7
23	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 2849-2861.	1.6	235
24	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
25	Frontline treatment with the combination obinutuzumab Ā± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	4.1	12
26	Efficacy and Safety of Zanubrutinib in Patients with Treatment-NaĀve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. <i>Blood</i> , 2020, 136, 11-12.	1.4	19
27	Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. <i>Blood</i> , 2020, 136, 39-41.	1.4	13
28	Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8015-8015.	1.6	5
29	Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2020, 164, 425-434.	0.6	0
30	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
31	Is percutaneous computed tomography-guided biopsy sufficient to establish indolent lymphoma transformation?. <i>Archives of Medical Science</i> , 2019, 15, 1443-1453.	0.9	1
32	Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S280-S281.	0.4	1
33	Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 9.	2.7	9
34	Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. <i>Leukemia Research</i> , 2019, 79, 17-21.	0.8	7
35	Single-agent ibrutinib in RESONATE-2Ā,Ĉ and RESONATEĀ,Ĉ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2749-2760.	1.8	9
36	Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry^{ĀĈ}. <i>Leukemia and Lymphoma</i> , 2019, 60, 748-755.	1.3	7

#	ARTICLE	IF	CITATIONS
37	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56.	10.7	448
38	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019, 134, 499-499.	1.4	23
39	Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. <i>Blood</i> , 2019, 134, 1766-1766.	1.4	0
40	Alternating R-CHOP and R-Cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 110-115.	1.7	18
41	Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. <i>Hematological Oncology</i> , 2018, 36, 773-778.	1.7	10
42	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. <i>Blood</i> , 2018, 132, 691-691.	1.4	8
43	Treatment of repeatedly relapsing chronic lymphocytic leukemia. <i>Onkologie (Czech Republic)</i> , 2018, 12, 139-143.	0.1	0
44	Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	2.2	5
45	Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation. <i>Acta Medica (Hradec Kralove)</i> , 2017, 60, 152-156.	0.5	3
46	Treatment of elderly and comorbid patients with chronic lymphocytic leukemia. <i>Onkologie (Czech) Tj ETQq0 0 0 rgBT₁/Overlock 10 Tf 50</i>	0.1	0
47	Practical approach to management of chronic lymphocytic leukemia. <i>Archives of Medical Science</i> , 2016, 2, 448-456.	0.9	5
48	Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. <i>Archives of Medical Science</i> , 2016, 2, 421-427.	0.9	8
49	Venous thromboembolism in patients with chronic lymphocytic leukemia. <i>Thrombosis Research</i> , 2015, 136, 1082-1086.	1.7	19
50	Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 5298-5298.	1.4	0
51	Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. <i>Neoplasma</i> , 2014, 62, 585-592.	1.6	4
52	Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group. <i>Blood</i> , 2014, 124, 4670-4670.	1.4	16
53	Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results. <i>Blood</i> , 2014, 124, 1720-1720.	1.4	0
54	The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. <i>European Journal of Haematology</i> , 2013, 90, 479-485.	2.2	11

#	ARTICLE	IF	CITATIONS
55	Rituximab and High-Dose Dexamethasone (R-dex) Is Effective In The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4184-4184.	1.4	0
56	Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 1278-1282.	0.8	25
57	Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. <i>International Journal of Hematology</i> , 2012, 96, 594-599.	1.6	11
58	Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases. <i>Acta OncolĀgica</i> , 2012, 51, 136-138.	1.8	10
59	The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen. <i>Blood</i> , 2012, 120, 4603-4603.	1.4	0
60	3.6 The Role of Imaging Methods in CLL: Significant Internal Lymphadenopathy is Frequent and Associated with Shorter Overall Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S199-S200.	0.4	1
61	Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4629-4629.	1.4	0